Durect corporation announces late-breaking oral presentation at the easl congress 2024 to discuss ahfirm phase 2b data in alcohol-associated hepatitis

Cupertino, calif. , april 30, 2024 /prnewswire/ -- durect corporation (nasdaq: drrx), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced acceptance of a late-breaking oral presentation at the european association for the study of the liver (easl) congress 2024 to take place june 5-8, 2024 in milan, italy.
DRRX Ratings Summary
DRRX Quant Ranking